Hypermutated circulating tumor DNA: correlation with response to checkpoint inhibitor–based immunotherapy
Y Khagi, AM Goodman, GA Daniels, SP Patel… - Clinical Cancer …, 2017 - AACR
… tumor DNA (ctDNA) and checkpoint inhibitor response. … with response to checkpoint
inhibitors in several malignancies (8… reactivated by checkpoint inhibitors, recognizes tumor cells …
inhibitors in several malignancies (8… reactivated by checkpoint inhibitors, recognizes tumor cells …
[HTML][HTML] Changes in circulating tumor DNA and outcomes in solid tumors treated with immune checkpoint inhibitors: a systematic review
L Al-Showbaki, B Wilson, F Tamimi… - … for Immunotherapy of …, 2023 - ncbi.nlm.nih.gov
… checkpoint inhibitors (ICIs). … tumor DNA (ctDNA) change in response to treatment is unclear,
especially in unselected advanced solid tumors treated with immune checkpoint inhibitors (…
especially in unselected advanced solid tumors treated with immune checkpoint inhibitors (…
The predicting role of circulating tumor DNA landscape in gastric cancer patients treated with immune checkpoint inhibitors
Y Jin, DL Chen, F Wang, C Yang, XX Chen, J You… - Molecular cancer, 2020 - Springer
A more common and noninvasive predicting biomarker for programmed cell death 1 (PD-1)
antibody remains to be explored. We assessed 46 patients with advanced gastric cancer …
antibody remains to be explored. We assessed 46 patients with advanced gastric cancer …
The role of circulating tumor DNA in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis
… Background: The use of circulating tumor DNA (ctDNA) to reflect clinical benefits of
advanced non-small cell lung cancer (NSCLC) patients during immune checkpoint inhibitor (ICI) …
advanced non-small cell lung cancer (NSCLC) patients during immune checkpoint inhibitor (ICI) …
Dynamic changes of circulating tumor DNA predict clinical outcome in patients with advanced non–small-cell lung cancer treated with immune checkpoint inhibitors
S Weber, P van der Leest, HC Donker… - JCO Precision …, 2021 - ascopubs.org
… checkpoint inhibitors (ICIs) in patients with non–small-cell lung cancer (NSCLC) is of high
clinical relevance. Given that circulating tumor DNA (ctDNA) reflects the total body tumor …
clinical relevance. Given that circulating tumor DNA (ctDNA) reflects the total body tumor …
Changes in circulating tumor DNA reflect clinical benefit across multiple studies of patients with non–small-cell lung cancer treated with immune checkpoint inhibitors
DM Vega, KK Nishimura, N Zariffa… - JCO Precision …, 2022 - ascopubs.org
PURPOSE As immune checkpoint inhibitors (ICI) become increasingly used in frontline
settings, identifying early indicators of response is needed. Recent studies suggest a role for …
settings, identifying early indicators of response is needed. Recent studies suggest a role for …
… tumor DNA as a biomarker for monitoring early treatment responses of patients with advanced lung adenocarcinoma receiving immune checkpoint inhibitors
P van der Leest, B Hiddinga, A Miedema… - Molecular …, 2021 - Wiley Online Library
… tumor DNA (ctDNA) level is a proxy of early tumor response to immunotherapy according to
response evaluation criteria in solid tumors … 100) receiving immune checkpoint inhibitors (ICI) …
response evaluation criteria in solid tumors … 100) receiving immune checkpoint inhibitors (ICI) …
Roles of circulating tumor DNA in PD-1/PD-L1 immune checkpoint inhibitors: Current evidence and future directions
Z Liu, Y Han, Q Dang, H Xu, Y Zhang, M Duo… - International …, 2022 - Elsevier
… treatments on tumors. In addition, ctDNA might be preferable to monitor tumor development
… in ctDNA could predict response to immune checkpoint inhibitor (ICI). Several studies have …
… in ctDNA could predict response to immune checkpoint inhibitor (ICI). Several studies have …
[HTML][HTML] Tumor DNA methylation profiles correlate with response to anti-PD-1 immune checkpoint inhibitor monotherapy in sarcoma patients
AM Starzer, AS Berghoff, R Hamacher… - … for Immunotherapy of …, 2021 - ncbi.nlm.nih.gov
… checkpoint inhibition, but predictive biomarkers are unknown. We analyzed tumor DNA …
cell death 1 (anti-PD-1) immune checkpoint inhibitor (ICI) therapy in patients with sarcoma. …
cell death 1 (anti-PD-1) immune checkpoint inhibitor (ICI) therapy in patients with sarcoma. …
[HTML][HTML] Early on-treatment circulating tumor DNA measurements and response to immune checkpoint inhibitors in advanced urothelial cancer
SH Tolmeijer, S van Wilpe, MJ Geerlings… - European Urology …, 2024 - Elsevier
… Change in on-treatment circulating tumor DNA (ctDNA) quantity and the durability of response
to immune checkpoint inhibitors (ICIs) in the discovery cohort. (A) Swimmer plot illustrating …
to immune checkpoint inhibitors (ICIs) in the discovery cohort. (A) Swimmer plot illustrating …
相关搜索
- immune checkpoint inhibitors
- cell lung cancer tumor dna
- tumor dna analysis
- single agent pembrolizumab tumor dna
- checkpoint inhibitor tumor dna methylation profiles
- tumor dna sequencing checkpoint blockade immunotherapy
- predictive biomarker tumor dna
- systematic review tumor dna
- checkpoint blockade tumor dna in patients
- dynamic changes tumor dna
- checkpoint inhibitors tumor dna measurements
- checkpoint inhibitors outcomes in solid tumors
- outcomes with immune checkpoint inhibitors icis
- early on treatment tumor dna measurements
- checkpoint inhibitors small cell lung cancer